A Comprehensive Approach to Unlocking the Full Potential of Neoantigen Cancer Vaccines
- Therapeutic cancer vaccines often fail to deliver durable clinical benefit because they stimulate only limited parts of the anti-tumour immune response.
- Effective vaccination requires validated tumour targets, strong immune stimulation, reliable manufacturing, and integration with modern immuno-oncology treatments.
- Black Canyon Bio’s SNAPduo™ platform combines shared tumour antigens, validated personalised neoantigens, and a potent adjuvant to enhance T-cell activation and potentially improve checkpoint inhibitor outcomes in HPV-associated and other solid tumours